BCL2 and malignant colon neoplasm: A combination of 4 and navitoclax (ABT263, an antagonist of the Bcl-2 family with selective binding to the apoptosis suppressors Bcl-2 and Bcl-XL) has shown synergistic effects on RAmutant colon cancer cells.